Azhraa Qinan Pranaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Azhraa Qinan Pranaya has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Aldy Heriwardito
Universitas Indonesia / Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia
1 shared publication - Anas Alatas
Universitas Indonesia / Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia
1 shared publication - Andy Omega
Universitas Indonesia / Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia
1 shared publication - Aries Perdana
Universitas Indonesia / Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia
1 shared publication - Atiqah Nurul Wardhany
Medical Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
1 shared publication Jane Elvina Sentosa
Universitas Indonesia / Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia
1 shared publication
Latest Publications
- Open Access
- 2 September 2026
- Published by CV. Akhbar Putra Mandiri in Scientific Journal
- Vol. 5 (5) , 445-462
Sedation for Pediatric Echocardiography in Congenital Heart Disease: Dexmedetomidine versus Chloral Hydrate
Background: Chloral hydrate is commonly used for paediatric transthoracic echocardiography (TTE) sedation, but safety concerns have prompted interest in alternatives. This meta-analysis compared intranasal dexmedetomidine with oral chloral hydrate for TTE sedation in children with known or suspected congenital heart disease (CHD). Method: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement and was registered in PROSPERO [CRD420261376912]. PubMed/MEDLINE, Europe PMC, Cochrane CENTRAL, and ClinicalTrials.gov were searched to 30 September 2026. Risk of bias was assessed with Cochrane tools and certainty of evidence with the Grading of Recommendations Assessment, Development and Evaluation approach. Data were pooled using random-effects models, with Hartung–Knapp adjustment when ≥3 studies contributed. Results: Four studies (one randomised trial and three cohort studies; 1414 children, 1187 in the primary analysis) were included. Single-dose sedation success did not differ in the randomised trial (risk ratio [RR] 1.02; 95% confidence interval [CI] 0.96–1.09), in the pooled non-randomised studies (RR 1.11; 95% CI 0.71–1.73), or overall (RR 1.08; 95% CI 0.85–1.36; very low certainty). Onset time and hypoxia did not differ significantly (very low certainty); rescue dose requirement was not pooled because its definition was not comparable across studies. Recovery time was shorter with dexmedetomidine (mean difference −9.96 min; 95% CI −18.71 to −1.22; low certainty). Bradycardia was more frequent with dexmedetomidine (RR 2.32; 95% CI 1.09–4.95; very low certainty), although no study reported its treatment. Conclusion: In children with known or suspected CHD, the two agents showed no clear difference in TTE sedation success, whereas bradycardia was more frequent with dexmedetomidine. Given low-to-very-low certainty of evidence, neither agent can be considered superior; adequately powered randomised trials are needed.
- 2 September 2026
- Published by CV. Akhbar Putra Mandiri in Scientific Journal
- Vol. 5 (5) , 445-462
Open AccessSedation for Pediatric Echocardiography in Congenital Heart Disease: Dexmedetomidine versus Chloral Hydrate
Background: Chloral hydrate is commonly used for paediatric transthoracic echocardiography (TTE) sedation, but safety concerns have prompted interest in alternatives. This meta-analysis compared intranasal dexmedetomidine with oral chloral hydrate for TTE sedation in children with known or suspected congenital heart disease (CHD). Method: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement and was registered in PROSPERO [CRD420261376912]. PubMed/MEDLINE, Europe PMC, Cochrane CENTRAL, and ClinicalTrials.gov were searched to 30 September 2026. Risk of bias was assessed with Cochrane tools and certainty of evidence with the Grading of Recommendations Assessment, Development and Evaluation approach. Data were pooled using random-effects models, with Hartung–Knapp adjustment when ≥3 studies contributed. Results: Four studies (one randomised trial and three cohort studies; 1414 children, 1187 in the primary analysis) were included. Single-dose sedation success did not differ in the randomised trial (risk ratio [RR] 1.02; 95% confidence interval [CI] 0.96–1.09), in the pooled non-randomised studies (RR 1.11; 95% CI 0.71–1.73), or overall (RR 1.08; 95% CI 0.85–1.36; very low certainty). Onset time and hypoxia did not differ significantly (very low certainty); rescue dose requirement was not pooled because its definition was not comparable across studies. Recovery time was shorter with dexmedetomidine (mean difference −9.96 min; 95% CI −18.71 to −1.22; low certainty). Bradycardia was more frequent with dexmedetomidine (RR 2.32; 95% CI 1.09–4.95; very low certainty), although no study reported its treatment. Conclusion: In children with known or suspected CHD, the two agents showed no clear difference in TTE sedation success, whereas bradycardia was more frequent with dexmedetomidine. Given low-to-very-low certainty of evidence, neither agent can be considered superior; adequately powered randomised trials are needed.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Biomolecular and Health Science Journal
- Vol. 9 (1) , 91-97
Challenging Penile Reconstruction in Adult Balanitis Xerotica Obliterans with Near-total Glans Fibrosis
Balanitis xerotica obliterans (BXO), the genital manifestation of lichen sclerosus, is a chronic inflammatory dermatosis that may cause progressive sclerosis and anatomical distortion. This case report presents a 58-year-old male with a 2-year history of penile deformity, circumferential hypopigmentation of the glans, sexual discomfort, and lower urinary tract symptoms. Initial assessment showed an International Prostate Symptom Score (IPSS) of 17 and an International Index of Erectile Function-5 (IIEF-5) score of 12. Physical examination revealed circumferential fibrosis with obliteration of the sulcus coronarius and destruction of approximately 70% of glans architecture, while the urethral meatus remained patent. Following excision of fibrotic tissue and penile mobilization, reconstruction was performed using a split-thickness skin graft (STSG) for a 3 cm × 5 cm circumferential defect. At 42-day follow-up, IPSS improved to 8 and IIEF-5–14. Advanced BXO may require reconstructive surgery, with STSG providing satisfactory functional and cosmetic outcomes.
- 1 January 2026
- Published by Wolters Kluwer Health in Biomolecular and Health Science Journal
- Vol. 9 (1) , 91-97
Open AccessChallenging Penile Reconstruction in Adult Balanitis Xerotica Obliterans with Near-total Glans Fibrosis
Balanitis xerotica obliterans (BXO), the genital manifestation of lichen sclerosus, is a chronic inflammatory dermatosis that may cause progressive sclerosis and anatomical distortion. This case report presents a 58-year-old male with a 2-year history of penile deformity, circumferential hypopigmentation of the glans, sexual discomfort, and lower urinary tract symptoms. Initial assessment showed an International Prostate Symptom Score (IPSS) of 17 and an International Index of Erectile Function-5 (IIEF-5) score of 12. Physical examination revealed circumferential fibrosis with obliteration of the sulcus coronarius and destruction of approximately 70% of glans architecture, while the urethral meatus remained patent. Following excision of fibrotic tissue and penile mobilization, reconstruction was performed using a split-thickness skin graft (STSG) for a 3 cm × 5 cm circumferential defect. At 42-day follow-up, IPSS improved to 8 and IIEF-5–14. Advanced BXO may require reconstructive surgery, with STSG providing satisfactory functional and cosmetic outcomes.